Date:11/4/2009

- --- ---- --- Net loss $(30,967) $(37,038) $(94,843) $(111,118) ======== ======== ======== ========= Basic and diluted net loss per share $(0.33) $(0.40) $(1.02) $(1.20) Shares used in computing basic and diluted net loss per share 92,789 92,425 92,621 92,413 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (unaudited) ASSETS September 30, 2009 December 31, 2008 (1) ------------------ ----------------- Current assets: Cash and cash equivalents $32,777 $155,584 Short-term investments 242,901 223,410 Accounts receivable, net of allowance 6,330 11,161 Inventory 8,930 9,319 Other current assets 7,275 6,746 ----- ----- Total current assets $298,213 $406,220 Property and equipment, net 74,624 73,578 Goodwill 76,501 76,501 Other assets 3,313 4,237 ----- ----- Total assets $452,651 $560,536 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $6,397 $13,832 Accrued compensation 9,711 11,570 Accrued clinical trial expens
'/>"/>

SOURCE Nektar Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors